Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.
Related Articles
T-DXd Breakthrough Designation Signals New Era for HER2-Positive Metastatic Breast Cancer
FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.
Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong | HKMJ
Hong Kong Med J 2025 Aug;31(4):312–5 | Epub 23 Jul 2025 https://doi.org/10.12809/hkmj2412259 © Hong Kong Academy of Medicine.
HLD-0915 Receives FDA Fast Track Designation for mCRPC Treatment
FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.
Improving Mental Health for Stem Cell Transplant Caregivers
A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.
Improving ACCESS to Stem Cell Transplant for All Patients
A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.
Final Analysis of TALAPRO-2 in mCRPC Confirms Significant Benefit
New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors.
Neoadjuvant Pembrolizumab and Enfortumab Vedotin Improve Outcomes in MIBC
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.
FDA Accepts NDA for Vepdegestrant in ER+/HER2- Metastatic Breast Cancer
The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.
The Targeted Pulse: Your Weekly Oncology Wrap-Up
Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.
Finding the Right Match: Who Should Opt for Anti–CTLA-4 and Programmed Cell Death Protein-1 Combination Therapy?
The emergence of immune checkpoint inhibitors (ICIs) has profoundly changed the landscape of cancer treatment. These agents have revolutionized the way we approach various malignancies,…